Skip to main content
Erschienen in: Current HIV/AIDS Reports 4/2014

01.12.2014 | Treatment as Prevention (RM Granich, Section Editor)

Cost-effectiveness Analysis Along the Continuum of HIV Care: How Can We Optimize the Effect of HIV Treatment as Prevention Programs?

verfasst von: B. Nosyk, E. Krebs, O. Eyawo, J. E. Min, R. Barrios, J. S. G. Montaner

Erschienen in: Current HIV/AIDS Reports | Ausgabe 4/2014

Einloggen, um Zugang zu erhalten

Abstract

The cascade of HIV care has been proposed as a useful tool to monitor health system performance across the key stages of HIV care delivery to reduce morbidity, mortality, and HIV transmission, the focal points of HIV Treatment as Prevention campaigns. Interventions to improve the cascade at its various stages may vary substantially in their ability to deliver health value per amount expended. In order to meet global antiretroviral treatment access targets, there is an urgent need to maximize the value of health spending by prioritizing cost-effective interventions. We executed a literature review on economic evaluations of interventions to improve specific stages of the cascade of HIV care. In total, 33 articles met the criteria for inclusion in the review, 22 (67 %) of which were published within the last 5 years. Nonetheless, substantial gaps in our knowledge remain, particularly for interventions to improve linkage and retention in HIV care in developed and developing-world settings and generalized and concentrated epidemics. We make the case here that the attention of scientists and policymakers needs to turn to the development, implementation, and rigorous evaluation of interventions to improve the various stages of the cascade of HIV care.
Literatur
1.
Zurück zum Zitat Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 1998;279(12):930–7.PubMedCrossRef Montaner JS, Reiss P, Cooper D, Vella S, Harris M, Conway B, et al. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV-infected patients: the INCAS Trial. JAMA. 1998;279(12):930–7.PubMedCrossRef
2.
Zurück zum Zitat Hogg RS, O’Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349(9061):1294.PubMedCrossRef Hogg RS, O’Shaughnessy MV, Gataric N, Yip B, Craib K, Schechter MT, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997;349(9061):1294.PubMedCrossRef
3.
Zurück zum Zitat Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–24.PubMedCrossRef Braitstein P, Brinkhof M, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–24.PubMedCrossRef
4.
Zurück zum Zitat Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.PubMedCentralPubMedCrossRef Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS ONE. 2013;8(12):e81355.PubMedCentralPubMedCrossRef
5.
Zurück zum Zitat Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedCrossRef Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365(6):493–505.PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013;27(7):1159–65.PubMedCrossRef Nosyk B, Audoin B, Beyrer C, Cahn P, Granich R, Havlir D, et al. Examining the evidence on the causal effect of HAART on transmission of HIV using the Bradford Hill criteria. AIDS. 2013;27(7):1159–65.PubMedCrossRef
7.
Zurück zum Zitat Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1-RNA concentrations and incidence of HIV-1 among injecting drug users: a prospective cohort study. BMJ. 2009;338:1191–4.CrossRef Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1-RNA concentrations and incidence of HIV-1 among injecting drug users: a prospective cohort study. BMJ. 2009;338:1191–4.CrossRef
8.
9.
Zurück zum Zitat Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedCentralPubMedCrossRef Gardner EM, McLees MP, Steiner JF, del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.PubMedCentralPubMedCrossRef
10.••
Zurück zum Zitat Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14(1):40–9. This articles provides a careful characterization of longitudinal changes in engagement with the cascade of HIV care using individual-level data. This mapping of the cascade of care helps understand what further efforts are needed to maximize the individual and public health benefits of Treatment as Prevention.PubMedCentralPubMedCrossRef Nosyk B, Montaner JS, Colley G, Lima VD, Chan K, Heath K, et al. The cascade of HIV care in British Columbia, Canada, 1996–2011: a population-based retrospective cohort study. Lancet Infect Dis. 2014;14(1):40–9. This articles provides a careful characterization of longitudinal changes in engagement with the cascade of HIV care using individual-level data. This mapping of the cascade of care helps understand what further efforts are needed to maximize the individual and public health benefits of Treatment as Prevention.PubMedCentralPubMedCrossRef
11.
Zurück zum Zitat Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367(9517):1193–208.PubMedCrossRef Laxminarayan R, Mills AJ, Breman JG, Measham AR, Alleyne G, Claeson M, et al. Advancement of global health: key messages from the Disease Control Priorities Project. Lancet. 2006;367(9517):1193–208.PubMedCrossRef
12.
Zurück zum Zitat Freedberg KA, Scharfstein JA, Seage III GR, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130–6.PubMedCrossRef Freedberg KA, Scharfstein JA, Seage III GR, Losina E, Weinstein MC, Craven DE, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA. 1998;279(2):130–6.PubMedCrossRef
13.
Zurück zum Zitat Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.PubMedCrossRef Sanders GD, Bayoumi AM, Sundaram V, Bilir SP, Neukermans CP, Rydzak CE, et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N Engl J Med. 2005;352(6):570–85.PubMedCrossRef
14.
Zurück zum Zitat Paltiel AD, Weinstein MC, Kimmel AD, Seage III GR, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.PubMedCrossRef Paltiel AD, Weinstein MC, Kimmel AD, Seage III GR, Losina E, Zhang H, et al. Expanded screening for HIV in the United States—an analysis of cost-effectiveness. N Engl J Med. 2005;352(6):586–95.PubMedCrossRef
15.
Zurück zum Zitat Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. JAIDS J Acquir Immune Defic Syndr. 2005;39(5):562–9. Mauskopf J, Kitahata M, Kauf T, Richter A, Tolson J. HIV antiretroviral treatment: early versus later. JAIDS J Acquir Immune Defic Syndr. 2005;39(5):562–9.
16.
Zurück zum Zitat Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. JAIDS J Acquir Immune Defic Syndr. 2013;64(2):183–9.CrossRef Farnham PG, Gopalappa C, Sansom SL, Hutchinson AB, Brooks JT, Weidle PJ, et al. Updates of lifetime costs of care and quality-of-life estimates for HIV-infected persons in the United States: late versus early diagnosis and entry into care. JAIDS J Acquir Immune Defic Syndr. 2013;64(2):183–9.CrossRef
17.
Zurück zum Zitat Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447–58.PubMedCrossRef Cremin I, Alsallaq R, Dybul M, Piot P, Garnett G, Hallett TB. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis. AIDS. 2013;27(3):447–58.PubMedCrossRef
18.
Zurück zum Zitat UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2013. UNAIDS. Global report: UNAIDS report on the global AIDS epidemic 2013. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2013.
19.
Zurück zum Zitat Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377(9782):2031–41.PubMedCrossRef Schwartländer B, Stover J, Hallett T, Atun R, Avila C, Gouws E, et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet. 2011;377(9782):2031–41.PubMedCrossRef
20.••
Zurück zum Zitat UNAIDS. UNAIDS report: ambitious treatment targets: writing the final chapter of the AIDS epidemic: Joint United Nations Programme on HIV/AIDS (UNAIDS)2014. UNAIDS has proposed an ambitious target explicitly focused on the cascade of HIV care of achieving 90 % of people living with HIV/AIDS diagnosed (PWHA), 90 % of those diagnosed on treatment and 90 % of those on treatment achieving viral suppression by 2020. UNAIDS. UNAIDS report: ambitious treatment targets: writing the final chapter of the AIDS epidemic: Joint United Nations Programme on HIV/AIDS (UNAIDS)2014. UNAIDS has proposed an ambitious target explicitly focused on the cascade of HIV care of achieving 90 % of people living with HIV/AIDS diagnosed (PWHA), 90 % of those diagnosed on treatment and 90 % of those on treatment achieving viral suppression by 2020.
21.
Zurück zum Zitat Gold MRSJ, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996. Gold MRSJ, Russell LB, Weinstein MC. Cost-effectiveness in health and medicine. New York, NY: Oxford University Press; 1996.
22.
Zurück zum Zitat Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, et al. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS ONE. 2014;9(1):e85197.PubMedCentralPubMedCrossRef Bassett IV, Govindasamy D, Erlwanger AS, Hyle EP, Kranzer K, van Schaik N, et al. Mobile HIV screening in Cape Town, South Africa: clinical impact, cost and cost-effectiveness. PLoS ONE. 2014;9(1):e85197.PubMedCentralPubMedCrossRef
23.
Zurück zum Zitat Bos JM, Fennema JS, Postma MJ. Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS. 2001;15(15):2031–6.PubMedCrossRef Bos JM, Fennema JS, Postma MJ. Cost-effectiveness of HIV screening of patients attending clinics for sexually transmitted diseases in Amsterdam. AIDS. 2001;15(15):2031–6.PubMedCrossRef
24.
Zurück zum Zitat Dowdy DW, Rodriguez RM, Bradley Hare C, Kaplan B. Cost‐effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. Acad Emerg Med. 2011;18(7):745–53.PubMedCrossRef Dowdy DW, Rodriguez RM, Bradley Hare C, Kaplan B. Cost‐effectiveness of targeted human immunodeficiency virus screening in an urban emergency department. Acad Emerg Med. 2011;18(7):745–53.PubMedCrossRef
25.
Zurück zum Zitat Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. JAIDS J Acquir Immune Defic Syndr. 2006;43:S113–8.CrossRef Freedberg KA, Hirschhorn LR, Schackman BR, Wolf LL, Martin LA, Weinstein MC, et al. Cost-effectiveness of an intervention to improve adherence to antiretroviral therapy in HIV-infected patients. JAIDS J Acquir Immune Defic Syndr. 2006;43:S113–8.CrossRef
26.
Zurück zum Zitat Fung IC, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7(1):195.PubMedCentralPubMedCrossRef Fung IC, Guinness L, Vickerman P, Watts C, Vannela G, Vadhvana J, et al. Modelling the impact and cost-effectiveness of the HIV intervention programme amongst commercial sex workers in Ahmedabad, Gujarat, India. BMC Public Health. 2007;7(1):195.PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Golden MR, Gift TL, Brewer DD, Fleming M, Hogben M, Lawrence JSS, et al. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006;20(15):1961–8.PubMedCrossRef Golden MR, Gift TL, Brewer DD, Fleming M, Hogben M, Lawrence JSS, et al. Peer referral for HIV case-finding among men who have sex with men. AIDS. 2006;20(15):1961–8.PubMedCrossRef
28.
Zurück zum Zitat Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. JAIDS J Acquir Immune Defic Syndr. 2012;61(1):99–105.CrossRef Gopalappa C, Farnham PG, Hutchinson AB, Sansom SL. Cost effectiveness of the National HIV/AIDS Strategy goal of increasing linkage to care for HIV-infected persons. JAIDS J Acquir Immune Defic Syndr. 2012;61(1):99–105.CrossRef
29.
Zurück zum Zitat Grabbe KL, Menzies N, Taegtmeyer M, Emukule G, Angala P, Mwega I, et al. Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization and cost-effectiveness. J Acquir Immune Defic Syndr (1999). 2010;54(3):317.CrossRef Grabbe KL, Menzies N, Taegtmeyer M, Emukule G, Angala P, Mwega I, et al. Increasing access to HIV counseling and testing through mobile services in Kenya: strategies, utilization and cost-effectiveness. J Acquir Immune Defic Syndr (1999). 2010;54(3):317.CrossRef
30.
Zurück zum Zitat Haukoos JS, Campbell JD, Conroy AA, Hopkins E, Bucossi MM, Sasson C, et al. Programmatic cost evaluation of nontargeted opt-out rapid HIV screening in the emergency department. PLoS ONE. 2013;8(12):e81565.PubMedCentralPubMedCrossRef Haukoos JS, Campbell JD, Conroy AA, Hopkins E, Bucossi MM, Sasson C, et al. Programmatic cost evaluation of nontargeted opt-out rapid HIV screening in the emergency department. PLoS ONE. 2013;8(12):e81565.PubMedCentralPubMedCrossRef
31.•
Zurück zum Zitat Kahn JG, Muraguri N, Harris B, Lugada E, Clasen T, Grabowsky M, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS ONE. 2012;7(2):e31316. This is an excellent example of evaluating innovative strategies to diagnose hard-to-reach clients in resource-limited settings. The short term integrated prevention campaign evaluated included HIV testing as well as provision of water filters, bed nets and other services.PubMedCentralPubMedCrossRef Kahn JG, Muraguri N, Harris B, Lugada E, Clasen T, Grabowsky M, et al. Integrated HIV testing, malaria, and diarrhea prevention campaign in Kenya: modeled health impact and cost-effectiveness. PLoS ONE. 2012;7(2):e31316. This is an excellent example of evaluating innovative strategies to diagnose hard-to-reach clients in resource-limited settings. The short term integrated prevention campaign evaluated included HIV testing as well as provision of water filters, bed nets and other services.PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d’Ivoire appraisal. PLoS Med. 2009;6(10):e1000173.PubMedCentralPubMedCrossRef Losina E, Touré H, Uhler LM, Anglaret X, Paltiel AD, Balestre E, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Cote d’Ivoire appraisal. PLoS Med. 2009;6(10):e1000173.PubMedCentralPubMedCrossRef
33.
Zurück zum Zitat Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS ONE. 2012;7(12):e51993.PubMedCentralPubMedCrossRef Marseille E, Giganti MJ, Mwango A, Chisembele-Taylor A, Mulenga L, Over M, et al. Taking ART to scale: determinants of the cost and cost-effectiveness of antiretroviral therapy in 45 clinical sites in Zambia. PLoS ONE. 2012;7(12):e51993.PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health econ Health Policy. 2009;7(4):229–43.PubMedCentralPubMedCrossRef Marseille E, Kahn JG, Pitter C, Bunnell R, Epalatai W, Jawe E, et al. The cost effectiveness of home-based provision of antiretroviral therapy in rural Uganda. Appl Health econ Health Policy. 2009;7(4):229–43.PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Mathoulin-Pelissier S, Salmi L-R, Fialon P, Salamon R. Cost-effectiveness of testing for human immunodeficiency virus and hepatitis C virus among blood transfusion recipients. Infect Control Hosp Epidemiol. 2003;24(2):132–6.PubMedCrossRef Mathoulin-Pelissier S, Salmi L-R, Fialon P, Salamon R. Cost-effectiveness of testing for human immunodeficiency virus and hepatitis C virus among blood transfusion recipients. Infect Control Hosp Epidemiol. 2003;24(2):132–6.PubMedCrossRef
36.•
Zurück zum Zitat Mulogo E, Batwala V, Nuwaha F, Aden A, Baine O. Cost effectiveness of facility and home based HIV voluntary counseling and testing strategies in rural Uganda. Afr Health Sci. 2013;13(2):423–9. This is an excellent example of evaluating innovative strategies to diagnose hard-to-reach clients in resource-limited settings. Home-based HIV screening in Uganda was found to be cheaper and cost less per infected individual identified compared to facility-based testing.PubMedCentralPubMed Mulogo E, Batwala V, Nuwaha F, Aden A, Baine O. Cost effectiveness of facility and home based HIV voluntary counseling and testing strategies in rural Uganda. Afr Health Sci. 2013;13(2):423–9. This is an excellent example of evaluating innovative strategies to diagnose hard-to-reach clients in resource-limited settings. Home-based HIV screening in Uganda was found to be cheaper and cost less per infected individual identified compared to facility-based testing.PubMedCentralPubMed
37.
Zurück zum Zitat Ownby RL, Waldrop-Valverde D, Jacobs RJ, Acevedo A, Caballero J. Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence. BMC Med Inform Decis Making. 2013;13(1):29.CrossRef Ownby RL, Waldrop-Valverde D, Jacobs RJ, Acevedo A, Caballero J. Cost effectiveness of a computer-delivered intervention to improve HIV medication adherence. BMC Med Inform Decis Making. 2013;13(1):29.CrossRef
38.
Zurück zum Zitat Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS. 2000;14(14):2159–69.PubMedCrossRef Phillips KA, Fernyak S. The cost-effectiveness of expanded HIV counselling and testing in primary care settings: a first look. AIDS. 2000;14(14):2159–69.PubMedCrossRef
39.
Zurück zum Zitat Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009;21(11):1388–94.PubMedCrossRef Renaud A, Basenya O, de Borman N, Greindl I, Meyer-Rath G. The cost effectiveness of integrated care for people living with HIV including antiretroviral treatment in a primary health care centre in Bujumbura, Burundi. AIDS Care. 2009;21(11):1388–94.PubMedCrossRef
40.
Zurück zum Zitat Ruger JP, Abdallah AB, Ng NY, Luekens C, Cottler L. Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial. AIDS and behavior. 2014:1–11. Ruger JP, Abdallah AB, Ng NY, Luekens C, Cottler L. Cost-effectiveness of interventions to prevent HIV and STDs among women: a randomized controlled trial. AIDS and behavior. 2014:1–11.
41.
Zurück zum Zitat Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25(6):556–63.PubMedCentralPubMedCrossRef Sanders GD, Anaya HD, Asch S, Hoang T, Golden JF, Bayoumi AM, et al. Cost-effectiveness of strategies to improve HIV testing and receipt of results: economic analysis of a randomized controlled trial. J Gen Intern Med. 2010;25(6):556–63.PubMedCentralPubMedCrossRef
42.•
Zurück zum Zitat Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013;128(1):90–7. There is an opportunity via community-based substance abuse treatment programs to implement on-site rapid HIV testing. This study, using data from a randomized trial conducted in 12 US community-based substance abuse treatment programs, determined on-site testing to be more efficient than referral for off-site testing.PubMedCentralPubMedCrossRef Schackman BR, Metsch LR, Colfax GN, Leff JA, Wong A, Scott CA, et al. The cost-effectiveness of rapid HIV testing in substance abuse treatment: results of a randomized trial. Drug Alcohol Depend. 2013;128(1):90–7. There is an opportunity via community-based substance abuse treatment programs to implement on-site rapid HIV testing. This study, using data from a randomized trial conducted in 12 US community-based substance abuse treatment programs, determined on-site testing to be more efficient than referral for off-site testing.PubMedCentralPubMedCrossRef
43.
Zurück zum Zitat Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123 Suppl 3:94.PubMedCentralPubMed Shrestha RK, Clark HA, Sansom SL, Song B, Buckendahl H, Calhoun CB, et al. Cost-effectiveness of finding new HIV diagnoses using rapid HIV testing in community-based organizations. Public Health Rep. 2008;123 Suppl 3:94.PubMedCentralPubMed
44.
Zurück zum Zitat Shrestha RK, Sansom SL, Kimbrough L, Hutchinson AB, Daltry D, Maldonado W, et al. Cost-effectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16(5):457–64.PubMedCrossRef Shrestha RK, Sansom SL, Kimbrough L, Hutchinson AB, Daltry D, Maldonado W, et al. Cost-effectiveness of using social networks to identify undiagnosed HIV infection among minority populations. J Public Health Manag Pract. 2010;16(5):457–64.PubMedCrossRef
45.
Zurück zum Zitat Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17(2):220–6.PubMedCentralCrossRef Spaulding AC, Pinkerton SD, Superak H, Cunningham MJ, Resch S, Jordan AO, et al. Cost analysis of enhancing linkages to HIV care following jail: a cost-effective intervention. AIDS Behav. 2013;17(2):220–6.PubMedCentralCrossRef
46.
Zurück zum Zitat Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, Kamenga C, et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet. 2000;356(9224):113–21.PubMedCrossRef Sweat M, Gregorich S, Sangiwa G, Furlonge C, Balmer D, Kamenga C, et al. Cost-effectiveness of voluntary HIV-1 counselling and testing in reducing sexual transmission of HIV-1 in Kenya and Tanzania. Lancet. 2000;356(9224):113–21.PubMedCrossRef
47.
Zurück zum Zitat Thielman NM, Chu HY, Ostermann J, Itemba DK, Mgonja A, Mtweve S, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health. 2006;96(1):114.PubMedCentralPubMedCrossRef Thielman NM, Chu HY, Ostermann J, Itemba DK, Mgonja A, Mtweve S, et al. Cost-effectiveness of free HIV voluntary counseling and testing through a community-based AIDS service organization in Northern Tanzania. Am J Public Health. 2006;96(1):114.PubMedCentralPubMedCrossRef
48.
Zurück zum Zitat Tole SP, Sanders GD, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, et al. Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS. 2009;20(1):46–51.PubMedCentralPubMedCrossRef Tole SP, Sanders GD, Bayoumi AM, Galvin CM, Vinichenko TN, Brandeau ML, et al. Cost-effectiveness of voluntary HIV screening in Russia. Int J STD AIDS. 2009;20(1):46–51.PubMedCentralPubMedCrossRef
49.
Zurück zum Zitat Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam’s injection-driven HIV epidemics. Drug Alcohol Depend. 2012;125(3):260–6.PubMedCrossRef Tran BX, Ohinmaa A, Duong AT, Nguyen LT, Vu PX, Mills S, et al. Cost-effectiveness of integrating methadone maintenance and antiretroviral treatment for HIV-positive drug users in Vietnam’s injection-driven HIV epidemics. Drug Alcohol Depend. 2012;125(3):260–6.PubMedCrossRef
50.
Zurück zum Zitat Tromp N, Siregar A, Leuwol B, Komarudin D, van der Ven A, van Crevel R, et al. Cost-effectiveness of scaling up voluntary counselling and testing in West-Java, Indonesia. Acta Medica Indonesiana. 2013;45(1):17–25.PubMed Tromp N, Siregar A, Leuwol B, Komarudin D, van der Ven A, van Crevel R, et al. Cost-effectiveness of scaling up voluntary counselling and testing in West-Java, Indonesia. Acta Medica Indonesiana. 2013;45(1):17–25.PubMed
51.
Zurück zum Zitat Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS ONE. 2010;5(9):e12747.PubMedCentralPubMedCrossRef Uhler LM, Kumarasamy N, Mayer KH, Saxena A, Losina E, Muniyandi M, et al. Cost-effectiveness of HIV testing referral strategies among tuberculosis patients in India. PLoS ONE. 2010;5(9):e12747.PubMedCentralPubMedCrossRef
52.
Zurück zum Zitat Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, et al. Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS ONE. 2011;6(10):e25575.PubMedCentralPubMedCrossRef Walensky RP, Morris BL, Reichmann WM, Paltiel AD, Arbelaez C, Donnell-Fink L, et al. Resource utilization and cost-effectiveness of counselor- vs. provider-based rapid point-of-care HIV screening in the emergency department. PLoS ONE. 2011;6(10):e25575.PubMedCentralPubMedCrossRef
53.
Zurück zum Zitat Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Medical Decision Making. 2008. Zaric GS, Bayoumi AM, Brandeau ML, Owens DK. The cost-effectiveness of counseling strategies to improve adherence to highly active antiretroviral therapy among men who have sex with men. Medical Decision Making. 2008.
54.
Zurück zum Zitat Public Health Agency of Canada. Summary: estimates of HIV prevalence and incidence in Canada, 2011, Control CfCDaI;2012. Public Health Agency of Canada. Summary: estimates of HIV prevalence and incidence in Canada, 2011, Control CfCDaI;2012.
55.
Zurück zum Zitat Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS ONE. 2014;9(2):e87872.PubMedCentralPubMedCrossRef Montaner JS, Lima VD, Harrigan PR, Lourenço L, Yip B, Nosyk B, et al. Expansion of HAART coverage is associated with sustained decreases in HIV/AIDS morbidity, mortality and HIV transmission: the “HIV Treatment as Prevention” experience in a Canadian setting. PLoS ONE. 2014;9(2):e87872.PubMedCentralPubMedCrossRef
56.
Zurück zum Zitat Centers for Disease Control and Prevention. HIV surveillance report. Atlanta, GA, U.S. Department of Health and Human Services CfDCaP;2011. Centers for Disease Control and Prevention. HIV surveillance report. Atlanta, GA, U.S. Department of Health and Human Services CfDCaP;2011.
57.
Zurück zum Zitat Walter L, Zunyou W. Testing and linkage to HIV care in China: a cluster randomized trial (CTN-0056). National Institutes of Health, National Institute on Drug Abuse; 2014. Walter L, Zunyou W. Testing and linkage to HIV care in China: a cluster randomized trial (CTN-0056). National Institutes of Health, National Institute on Drug Abuse; 2014.
58.
Zurück zum Zitat Bärnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell M-L. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS. 2008;22(1):139–44.PubMedCrossRef Bärnighausen T, Tanser F, Gqwede Z, Mbizana C, Herbst K, Newell M-L. High HIV incidence in a community with high HIV prevalence in rural South Africa: findings from a prospective population-based study. AIDS. 2008;22(1):139–44.PubMedCrossRef
59.
Zurück zum Zitat Kohler H-P, Thornton RL. Conditional cash transfers and HIV/AIDS prevention: unconditionally promising? The World Bank Economic Review. 2011. Kohler H-P, Thornton RL. Conditional cash transfers and HIV/AIDS prevention: unconditionally promising? The World Bank Economic Review. 2011.
60.
Zurück zum Zitat Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012;5(4):320–31.PubMed Schierenberg A, van Amsterdam J, van den Brink W, Goudriaan AE. Efficacy of contingency management for cocaine dependence treatment: a review of the evidence. Curr Drug Abuse Rev. 2012;5(4):320–31.PubMed
61.
Zurück zum Zitat Poon AF, Walker LW, Murray H, McCloskey RM, Harrigan PR, Liang RH. Mapping the shapes of phylogenetic trees from human and zoonotic RNA viruses. PLoS ONE. 2013;8(11):e78122.PubMedCentralPubMedCrossRef Poon AF, Walker LW, Murray H, McCloskey RM, Harrigan PR, Liang RH. Mapping the shapes of phylogenetic trees from human and zoonotic RNA viruses. PLoS ONE. 2013;8(11):e78122.PubMedCentralPubMedCrossRef
62.
Zurück zum Zitat Poon AF, Joy JB, Woods CK, Shurgold S, Colley G, Brumme CJ et al. Population-level phylo genetic analyses quantify the impact of clinical, demographic, and risk factors on variations in HIV transmission rates in British Columbia, Canada. Canadian Association of HIV/AIDS Research 23rd Annual Conference; May 2014; St. John’s, Newfoundland.2014. Poon AF, Joy JB, Woods CK, Shurgold S, Colley G, Brumme CJ et al. Population-level phylo genetic analyses quantify the impact of clinical, demographic, and risk factors on variations in HIV transmission rates in British Columbia, Canada. Canadian Association of HIV/AIDS Research 23rd Annual Conference; May 2014; St. John’s, Newfoundland.2014.
63.
Zurück zum Zitat Klein DJ, Bershteyn A, Eckhoff PA. Dropout and re-enrollment: implications for epidemiological projections of treatment programs. AIDS. 2014;28:S47–59.PubMedCrossRef Klein DJ, Bershteyn A, Eckhoff PA. Dropout and re-enrollment: implications for epidemiological projections of treatment programs. AIDS. 2014;28:S47–59.PubMedCrossRef
64.
Zurück zum Zitat Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;11(12):942–51.PubMedCentralPubMedCrossRef Bärnighausen T, Chaiyachati K, Chimbindi N, Peoples A, Haberer J, Newell M-L. Interventions to increase antiretroviral adherence in sub-Saharan Africa: a systematic review of evaluation studies. Lancet Infect Dis. 2011;11(12):942–51.PubMedCentralPubMedCrossRef
65.
Zurück zum Zitat Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392–400.PubMedCentralPubMedCrossRef Walensky RP, Paltiel AD, Losina E, Morris BL, Scott CA, Rhode ER, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis. 2010;51(4):392–400.PubMedCentralPubMedCrossRef
66.
Zurück zum Zitat Gustafson R, Montaner J, Sibbald B. Seek and treat to optimize HIV and AIDS prevention. Can Med Assoc J. 2012;184(18):1971.CrossRef Gustafson R, Montaner J, Sibbald B. Seek and treat to optimize HIV and AIDS prevention. Can Med Assoc J. 2012;184(18):1971.CrossRef
67.
Zurück zum Zitat Kinsler JJ, Sayles JN, Cunningham WE, Mahajan A. Preference for physician vs. nurse-initiated opt-out screening on HIV test acceptance. AIDS Care. 2013;25(11):1442–5.PubMedCrossRef Kinsler JJ, Sayles JN, Cunningham WE, Mahajan A. Preference for physician vs. nurse-initiated opt-out screening on HIV test acceptance. AIDS Care. 2013;25(11):1442–5.PubMedCrossRef
68.
Zurück zum Zitat Government of the District of Columbia Department of Health. DC jurisdictional HIV prevention plan 2012–2015. 2012. Government of the District of Columbia Department of Health. DC jurisdictional HIV prevention plan 2012–2015. 2012.
69.
Zurück zum Zitat Government of the District of Columbia. Annual report 2011, Services DoHaH;2012. Government of the District of Columbia. Annual report 2011, Services DoHaH;2012.
70.
Zurück zum Zitat Centers for Disease Control and Prevention. HIV testing at CDC funded sites, United, States, Puerto Rico and the U.S. Virgin Islands, 2011. Atlanta, GA, Department of Health and Human Services CfDCaP;2013. Centers for Disease Control and Prevention. HIV testing at CDC funded sites, United, States, Puerto Rico and the U.S. Virgin Islands, 2011. Atlanta, GA, Department of Health and Human Services CfDCaP;2013.
71.
Zurück zum Zitat Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost‐effectiveness analysis alongside clinical trials: the ISPOR RCT‐CEA Task Force report. Value Health. 2005;8(5):521–33.PubMedCrossRef Ramsey S, Willke R, Briggs A, Brown R, Buxton M, Chawla A, et al. Good research practices for cost‐effectiveness analysis alongside clinical trials: the ISPOR RCT‐CEA Task Force report. Value Health. 2005;8(5):521–33.PubMedCrossRef
72.
Zurück zum Zitat Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. PharmacoEconomics. 2000;17(5):461–77.PubMedCrossRef Sculpher M, Fenwick E, Claxton K. Assessing quality in decision analytic cost-effectiveness models. PharmacoEconomics. 2000;17(5):461–77.PubMedCrossRef
73.
Zurück zum Zitat Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9(7):e1001247.PubMedCentralPubMedCrossRef Meyer-Rath G, Over M. HIV treatment as prevention: modelling the cost of antiretroviral treatment—state of the art and future directions. PLoS Med. 2012;9(7):e1001247.PubMedCentralPubMedCrossRef
Metadaten
Titel
Cost-effectiveness Analysis Along the Continuum of HIV Care: How Can We Optimize the Effect of HIV Treatment as Prevention Programs?
verfasst von
B. Nosyk
E. Krebs
O. Eyawo
J. E. Min
R. Barrios
J. S. G. Montaner
Publikationsdatum
01.12.2014
Verlag
Springer US
Erschienen in
Current HIV/AIDS Reports / Ausgabe 4/2014
Print ISSN: 1548-3568
Elektronische ISSN: 1548-3576
DOI
https://doi.org/10.1007/s11904-014-0227-7

Weitere Artikel der Ausgabe 4/2014

Current HIV/AIDS Reports 4/2014 Zur Ausgabe

Treatment as Prevention (RM Granich, Section Editor)

Treatment as Prevention—Where Next?

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Review of Recent Behavioral Interventions Targeting Older Adults Living with HIV/AIDS

Behavioral-Bio-Medical Interface (JL Brown and RJ DiClemente, Section Editors)

Optimizing ART Adherence: Update for HIV Treatment and Prevention

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

So sicher sind Tattoos: Neue Daten zur Risikobewertung

22.05.2024 Melanom Nachrichten

Das größte medizinische Problem bei Tattoos bleiben allergische Reaktionen. Melanome werden dadurch offensichtlich nicht gefördert, die Farbpigmente könnten aber andere Tumoren begünstigen.

CAR-M-Zellen: Warten auf das große Fressen

22.05.2024 Onkologische Immuntherapie Nachrichten

Auch myeloide Immunzellen lassen sich mit chimären Antigenrezeptoren gegen Tumoren ausstatten. Solche CAR-Fresszell-Therapien werden jetzt für solide Tumoren entwickelt. Künftig soll dieser Prozess nicht mehr ex vivo, sondern per mRNA im Körper der Betroffenen erfolgen.

Frühzeitige HbA1c-Kontrolle macht sich lebenslang bemerkbar

22.05.2024 Typ-2-Diabetes Nachrichten

Menschen mit Typ-2-Diabetes von Anfang an intensiv BZ-senkend zu behandeln, wirkt sich positiv auf Komplikationen und Mortalität aus – und das offenbar lebenslang, wie eine weitere Nachfolgeuntersuchung der UKPD-Studie nahelegt.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.